AUAUniversity Podcast Series: Episode No. 7

AUA2019 023IC - Chemotherapy And Immunotherapy Options For Genitourinary Malignancies

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

Instructional Course Director(s)
Costas Lallas, MD
Thomas Jefferson University Hospital

Instructional Course Faculty(s)
Anne Calvaresi, DNP, CRNP
Thomas Jefferson University

Edouard Trabulsi, MD, FACS
Sidney Kimmel Medical College at Thomas Jefferson University

Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, prostate, and testis cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a question and answer period. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects.

Learning Objectives:

  • Describe the standard of care chemotherapy regimens for genitourinary malignancies
  • Recall both historic and newer immunotherapy options in the treatment of genitourinary malignancies, including recently approved checkpoint inhibitors and antibody-drug conjugates.
  • Outline the mechanism of action of common chemotherapy and immunotherapy regimens for genitourinary malignancies.
  • Recognize and manage the adverse events related to these agents.
  • Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies.
  • List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.